Tau exacerbates the development of distinct neuropsychiatric symptoms in late braak stage – the head study
CI individuals had significantly higher NPI-Q score and Braak VI PET SUVR than CU individuals (Table 1). NPI-Q score was significantly associated with tau-PET in the periRolandic and supplementary motor cortex (Figures 1A). Linear regression showed that NPI-Q associates with tau-PET in the Braak stage VI (Figure 1B). Leave-one-out regression analysis revealed that delusions, motor disturbances, and anxiety contributed most to the association between tau-PET and NPS (Figure 2A, C). These domains presented a higher magnitude of association compared to each other NPI-Q domain (Figure 2B). Notably, irritability, agitation, and disinhibition exerted a negative effect to the association, emphasizing that tau may not play a role in the development of these symptoms (Figure 2A, D) CONCLUSION: Our study supports previous evidence suggesting that irritability and agitation may not be triggered by tau, but rather by other pathological process such as neuroinflammation. These findings provide additional rationale for the therapeutics aiming to mitigate irritability and agitation in AD patients.
Authors
- Val J. Lowe (ORCID: https://orcid.org/0000-0002-5612-1667)
- Dana Tudorascu (ORCID: https://orcid.org/0000-0003-4675-3692)
- Tharick Ali Pascoal (ORCID: https://orcid.org/0000-0001-9057-8014)
- João Pedro Ferrari‐Souza (ORCID: https://orcid.org/0000-0003-2183-1551)
- Guilherme Povala (ORCID: https://orcid.org/0000-0002-2023-6569)
- Douglas Teixeira Leffa (ORCID: https://orcid.org/0000-0002-4890-8451)
- Eduardo Rigon Zimmer (ORCID: https://orcid.org/0000-0002-5349-0053)
- Belén Pascual (ORCID: https://orcid.org/0000-0002-4467-7406)
- Carolina Soares (ORCID: https://orcid.org/0000-0002-2338-4495)
- Lucas Porcello Schilling (ORCID: https://orcid.org/0000-0002-9923-6982)
- Guilherme Bauer‐Negrini (ORCID: https://orcid.org/0000-0003-0956-557X)
- Pâmela C.L. Ferreira (ORCID: https://orcid.org/0000-0003-2134-9829)
- Bruna Bellaver (ORCID: https://orcid.org/0000-0002-2212-3373)
- David N. Soleimani‐Meigooni (ORCID: https://orcid.org/0000-0003-4197-3039)
- Sarah Abbas
- Suzanne L. Baker (ORCID: https://orcid.org/0000-0003-0209-3127)
- Firoza Zubeida Lussier (ORCID: https://orcid.org/0000-0002-6877-4825)
- Cristiano Schaffer Aguzzoli (ORCID: https://orcid.org/0000-0002-7378-3830)
- Lívia Amaral (ORCID: https://orcid.org/0009-0005-4488-763X)
- Hussein Zalzale
- Francieli Rohden (ORCID: https://orcid.org/0000-0002-9232-7371)
- Brian A. Gordon (ORCID: https://orcid.org/0000-0003-2109-2955)
- Pedro Rosa‐Neto (ORCID: https://orcid.org/0000-0001-9116-1376)
- Hwamee Oh (ORCID: https://orcid.org/0000-0003-1156-5704)
Institutions
- Houston Methodist (US)
- Universidade Federal do Rio Grande do Sul (BR)
- Lawrence Berkeley National Laboratory (US)
- University of Pittsburgh (US)
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- Brown University (US)
- Instituto do Cérebro (BR)
- Mayo Clinic in Arizona (US)
- Global Brain Health Institute (US)
- McGill University (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/alz.092310
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.33